Compounds that interfere with early stages of cancer formation are particularly appropriate for mutation carriers and evidence indicates that risk reduction strategies focused on patients harboring germ-line BRCA1 mutations are effective [87–89]. The gene discussed is BRCA1; the disease is cancer.